Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)

Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)

Sponsors and Collaborators
M.D. Anderson Cancer Center
GlaxoSmithKline

Contact
Nizar M. Tannir, MD
713-792-2830

Principal Investigator
Nizar M. Tannir, MD
UT MD Anderson Cancer Center

ClinicalTrials.gov Identifier
NCT01392183

Loading links....
You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters